Conditions

However, in 2016, Novo Nordisk halted the development of their basal oral insulin tablet.

Results presented in the ADA 77th Scientific Sessions suggests the use of an investigational glucagon-blocking agent can improve glycemic levels and reduce insulin requirements.

Results from two studies demonstrate improved glycemic control, reduction in nighttime- and exercise-induced hypoglycemia with the use of hybrid closed-loop systems.

The DEVOTE trial compared cardiovascular safety in two basal insulins; insulin degludec was found to have additional benefits.

Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease among other benefits with metformin in type 1 diabetes patients.

Results from two ODYSSEY studies indicate the favorable lipid lowering effects of Alirocumab, a PCSK9 inhibitor, in type 2 diabetes patients can potentially reduce the risk of cardiovascular disease.

In this week's Homerun Slides, a summary of the clinical trials assessing the impact of intensive therapy in type 2 diabetes.

New study shows lower risk for poor cardiovascular outcomes for T2 patients on glucagonlike peptide-1 receptor agonists.

In addition to psychosocial risk factors, disease related factors may also be contributing to bulimic symptoms.

Placing newborns in prospective studies to conduct genetic screenings with follow up may reduce the risk of DKA at diagnosis of type 1.